# AKEBIA THERAPEUTICS, INC. (AKBA) · Edgar & Edgarette company card

> Akebia Therapeutics (AKBA) grew revenue 47.5% in FY2025 to $236 million, operating margin 9.9% against a -3.8% median for pharmaceutical preparations, equity 8.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1517022 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AKBA) · [JSON](https://www.pops4.com/boards/company/AKBA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $236M |
| Revenue growth, 1 year | 47.5% |
| Revenue growth per year | 2.8% |
| Operating margin | 9.9% (prior year -31.5%) |
| Net margin | -2.3% |
| Operating cash flow | $68M |
| Capital spending | $291,000 |
| Free cash flow | $68M |
| Cash | $185M |
| Long-term debt | $48M |
| Total assets | $377M |
| Total equity | $33M |
| Equity ÷ assets | 8.7% |
| Return on equity | -16.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -12.49 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -3.29 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; revenue is hard to predict: its 80% range is ±44%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $236.2M (FY2025), total debt $48.3M. Experience: revenue up 47.5% on the year, up 2.8% a year over 4 years; operating margin 9.9%, up from -31.5%. Soundness: equity 8.7% of assets, return on equity -16.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $175.6M and $447.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $138.7M to $571.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 9.9% against a -3.8% median; growth 47.5% against 13.7%.

Range logged 2026-10-15, receipt a80d31786dde1e90, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-10-23 ([filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/0001517022-26-000075-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-14 ([filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/0001517022-26-000071-index.htm))

## Recent filings

- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000089/0001517022-26-000089-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/0001517022-26-000084-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/0001517022-26-000083-index.htm)
- 8-K · filed 2026-10-23 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/0001517022-26-000075-index.htm)
- 8-K · filed 2026-10-14 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/0001517022-26-000071-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/0001517022-26-000051-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001517022.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1517022

## Cite

POPS4, Edgar & Edgarette: AKEBIA THERAPEUTICS, INC. (AKBA) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/AKBA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

